WO2010120121A2 - 표적 특이적 비항체 단백질 및 이의 제조 방법 - Google Patents
표적 특이적 비항체 단백질 및 이의 제조 방법 Download PDFInfo
- Publication number
- WO2010120121A2 WO2010120121A2 PCT/KR2010/002318 KR2010002318W WO2010120121A2 WO 2010120121 A2 WO2010120121 A2 WO 2010120121A2 KR 2010002318 W KR2010002318 W KR 2010002318W WO 2010120121 A2 WO2010120121 A2 WO 2010120121A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- protein
- antibody
- target
- antibody protein
- amino acid
- Prior art date
Links
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 237
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 237
- 238000000034 method Methods 0.000 title claims abstract description 39
- 102000001301 EGF receptor Human genes 0.000 claims abstract description 82
- 108060006698 EGF receptor Proteins 0.000 claims abstract description 82
- 125000000539 amino acid group Chemical group 0.000 claims abstract description 32
- 239000000203 mixture Substances 0.000 claims abstract description 19
- 238000003032 molecular docking Methods 0.000 claims description 29
- 102000003839 Human Proteins Human genes 0.000 claims description 18
- 108090000144 Human Proteins Proteins 0.000 claims description 18
- 238000004088 simulation Methods 0.000 claims description 15
- 238000004519 manufacturing process Methods 0.000 claims description 14
- 150000007523 nucleic acids Chemical class 0.000 claims description 14
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 11
- 108020004707 nucleic acids Proteins 0.000 claims description 11
- 102000039446 nucleic acids Human genes 0.000 claims description 11
- 238000002823 phage display Methods 0.000 claims description 10
- 239000013598 vector Substances 0.000 claims description 10
- 239000000710 homodimer Substances 0.000 claims description 7
- 230000003993 interaction Effects 0.000 claims description 7
- 108010052285 Membrane Proteins Proteins 0.000 claims description 4
- 239000000178 monomer Substances 0.000 claims description 4
- 102000018697 Membrane Proteins Human genes 0.000 claims description 2
- 230000005856 abnormality Effects 0.000 claims description 2
- 239000012830 cancer therapeutic Substances 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 abstract description 21
- 150000001413 amino acids Chemical class 0.000 description 21
- 210000004027 cell Anatomy 0.000 description 20
- 201000011510 cancer Diseases 0.000 description 19
- 230000009918 complex formation Effects 0.000 description 12
- 230000000295 complement effect Effects 0.000 description 9
- 230000008569 process Effects 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 238000003041 virtual screening Methods 0.000 description 7
- 238000004364 calculation method Methods 0.000 description 6
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 5
- 239000011230 binding agent Substances 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000006916 protein interaction Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 102000023732 binding proteins Human genes 0.000 description 4
- 108091008324 binding proteins Proteins 0.000 description 4
- 238000010276 construction Methods 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000004091 panning Methods 0.000 description 4
- 238000002626 targeted therapy Methods 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000001506 calcium phosphate Substances 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 239000002547 new drug Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000004850 protein–protein interaction Effects 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- DVLFYONBTKHTER-UHFFFAOYSA-N 3-(N-morpholino)propanesulfonic acid Chemical compound OS(=O)(=O)CCCN1CCOCC1 DVLFYONBTKHTER-UHFFFAOYSA-N 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 101710167800 Capsid assembly scaffolding protein Proteins 0.000 description 2
- 102000009465 Growth Factor Receptors Human genes 0.000 description 2
- 108010009202 Growth Factor Receptors Proteins 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 101710130420 Probable capsid assembly scaffolding protein Proteins 0.000 description 2
- 101710204410 Scaffold protein Proteins 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000007972 injectable composition Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000008863 intramolecular interaction Effects 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- -1 precipitation Chemical compound 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 102000035160 transmembrane proteins Human genes 0.000 description 2
- 108091005703 transmembrane proteins Proteins 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- IVLXQGJVBGMLRR-UHFFFAOYSA-N 2-aminoacetic acid;hydron;chloride Chemical compound Cl.NCC(O)=O IVLXQGJVBGMLRR-UHFFFAOYSA-N 0.000 description 1
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 229920000945 Amylopectin Polymers 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 241001050985 Disco Species 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000851181 Homo sapiens Epidermal growth factor receptor Proteins 0.000 description 1
- 108020005350 Initiator Codon Proteins 0.000 description 1
- 244000017020 Ipomoea batatas Species 0.000 description 1
- 235000002678 Ipomoea batatas Nutrition 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 241000235058 Komagataella pastoris Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 239000007993 MOPS buffer Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241000221961 Neurospora crassa Species 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 241000588770 Proteus mirabilis Species 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 241000235346 Schizosaccharomyces Species 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 108020005038 Terminator Codon Proteins 0.000 description 1
- 241000009298 Trigla lyra Species 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 238000003314 affinity selection Methods 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 229940125644 antibody drug Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 239000013602 bacteriophage vector Substances 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 238000010170 biological method Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000013601 cosmid vector Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940095399 enema Drugs 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000010429 evolutionary process Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 201000010175 gallbladder cancer Diseases 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 102000045108 human EGFR Human genes 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000001024 immunotherapeutic effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 150000002605 large molecules Chemical class 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000010687 lubricating oil Substances 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 210000001938 protoplast Anatomy 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- HBMJWWWQQXIZIP-UHFFFAOYSA-N silicon carbide Chemical compound [Si+]#[C-] HBMJWWWQQXIZIP-UHFFFAOYSA-N 0.000 description 1
- 229910010271 silicon carbide Inorganic materials 0.000 description 1
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000003033 structure based virtual screening Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000012137 tryptone Substances 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1089—Design, preparation, screening or analysis of libraries using computer algorithms
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
- G16B15/30—Drug targeting using structural data; Docking or binding prediction
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B35/00—ICT specially adapted for in silico combinatorial libraries of nucleic acids, proteins or peptides
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B35/00—ICT specially adapted for in silico combinatorial libraries of nucleic acids, proteins or peptides
- G16B35/20—Screening of libraries
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
- G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
- G16C20/60—In silico combinatorial chemistry
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
Definitions
- the present invention relates to a method for producing a target specific non-antibody protein, and more particularly to selecting a non-antibody protein having structural complementarity with a target site of a target protein in a library of non-antibody proteins, and selecting the selected non-antibody protein and the target protein.
- a non-antibody protein having a stable binding energy is selected from the selected non-antibody proteins, and an amino acid residue having a high binding energy is selected from the amino acid residues in direct contact with the selected non-antibody protein and the target protein.
- It relates to a method for producing a target specific non-antibody protein comprising the step of replacing the selected amino acid residues with low binding energy amino acid residues.
- the present invention also relates to a target specific non-antibody that specifically binds to EGFR (Epidermal Growth Factor Receptor) domain 2 prepared by the method, and a composition for treating cancer comprising the same.
- Antibodies have been conventionally used as protein new drugs for treating diseases.
- Antibodies are proteins produced by the stimulation of antigens in B cells of white blood cells in the immune system. When an antigen is encountered, the antibody recognizes the antigen through a receptor in the cell and binds through the receptor.
- antibodies are characterized by their specific recognition of specific proteins and their strong binding. These properties have been used to bind proteins that cause diseases such as cancer and prevent malicious protein interactions.
- Non-antibody proteins are a new class of new drugs for patient-specific targeted therapies, and have recently received new attention as an alternative to overcome the limitations of therapeutic antibodies that are currently emerging in the drug market.
- Such non-antibody proteins have the purpose of selectively recognizing and strongly binding to a specific target molecule such as an antibody therapeutic agent, thereby inhibiting the activity of a desired target molecule and preventing or progressing various diseases such as cancer and autoimmune diseases.
- the existing non-antibody proteins are produced based on only one scaffold regardless of the structure of the target molecule, like the existing antibodies. Proteins are based on a three-dimensional structure, so Lego blocks intertwine with each other, making it ideal to use a custom protein scaffold that is specific to a specific target.
- a non-antibody protein having a complementary structure that can specifically bind to a target it is difficult to find a target-specific non-antibody protein and use it for the treatment of a disease. There was a problem. In particular, since the structure and type of the protein is very diverse, there was a problem that it is impossible to confirm through experiments which of the many proteins binds to a specific target.
- the binding site to the target molecule is determined by chance, and this binding site cannot be designed beforehand.
- the site of the target protein to which the existing non-antibody proteins and antibodies can bind is very limited structurally, especially when the target site is concave (access) was inherently impossible. Therefore, in order to find a protein that binds to a desired site among the proteins that bind to the target molecule, there has been a problem of undergoing a complicated candidate selection process for a long time after the target binding site identification experiment (epitope mapping).
- the inventors have made diligent efforts to find methods for producing target specific non-antibody proteins and, based on the structural libraries of proteins whose tertiary structures have been determined, provide structural complementarity through virtual screening for desired target sites of a given target protein.
- This highest optimal protein scaffold is selected and amino acids that interfere with binding to the target molecule are randomized using phage display and biopanning to target optimal binding to a specific site of a predetermined target protein. It was confirmed that specific non-antibody proteins can be prepared.
- the present invention was completed by preparing a non-antibody protein that targets domain 2 of EGFR (Epdermal Growth Factor Receptor), which is an anticancer target, and confirming the binding strength with the target.
- EGFR Epidermal Growth Factor Receptor
- One object of the present invention is to select a non-antibody protein having structural complementarity with a target site of a target protein in a library of non-antibody proteins; (b) calculating the binding energy of the selected non-antibody protein with the target protein; (c) selecting a non-antibody protein having stable binding energy among the selected non-antibody proteins: (d) selecting an amino acid residue having a high binding energy among amino acid residues in direct contact with the selected non-antibody protein and a target protein; step; And (e) substituting the amino acid residue selected in step (d) with an amino acid residue having a low binding energy.
- Another object of the present invention is to provide a target specific non-antibody protein that specifically binds to EGFR domain 2.
- Still another object of the present invention is to provide a nucleic acid encoding a target specific non-antibody protein that specifically binds the EGFR domain 2, a vector comprising the nucleic acid, or a transformant transformed with the vector.
- Still another object of the present invention is to provide a composition for treating cancer comprising a target specific non-antibody protein that specifically binds to EGFR domain 2.
- the base technology that can be developed bio-new drugs that can be applied to a variety of targets that were impossible to access existing materials such as existing antibody drugs, protein drugs, aptamers (platform technology) can be provided.
- the method of the present invention is expected to enable the development of innovative patient-targeted targeted therapies, with a very large social and economic impact.
- the target specific protein that inhibits the EGFR domain 2 of the present invention specifically inhibits the activity of EGFR by a new concept of EGFR, which is a target of cancer treatment, to selectively attack only cancer cells, not normal cells, thereby providing an effective cancer treatment effect. You can do it.
- FIG. 1 illustrates a schematic method of Protein Engineering with Laboratory Evolution & Extensive Computaion (PELEX), a method of the present invention for designing a scaffold specific for binding sites.
- PELEX Protein Engineering with Laboratory Evolution & Extensive Computaion
- (a) is a flowchart showing PELEX in two steps.
- a virtual screening step that performs virtual screening, including docking simulations and complex formation energy calculations and directional evolution of the screened scaffolds to optimize binding affinity with predetermined binding sites. It consists of.
- (B) is a diagram showing the selection of protein scaffolds having a shape complementary to a predetermined binding site of the target protein based on the human protein scaffold structure library and the docking simulation.
- Large-scale protein scaffold libraries include all known human protein structures.
- (c) shows the selection of a scaffold exhibiting stable binding energy for further optimization through directional evolution by calculation of complex formation energy using the screened docking structure.
- (d) is a diagram showing directional evolution using sequence randomization and phage display for fine tuning of scaffolds specific for binding sites. In this process, residues that are not stable for binding were randomized to optimize the affinity between the target and the scaffold.
- the underlined amino acid is the amino acid of the EGFR domain 2 site, which is the 166th to 309th amino acid portion. 28 amino acid residues indicated in the box were selected as candidates for amino acids participating in the binding as surface residues.
- FIG. 3 is a diagram showing the mechanism of activation of EGFR and the mechanism of activity of scaffolds designed to inhibit the activity of EGFR.
- (c) illustrates the mechanism of inhibiting the activity of EGFR by preventing the designed scaffold from binding to EGFR domain 2 and becoming a homodimer.
- binding proteins recognize only activated EGFR, not auto-inhibited EGFR.
- (b) shows the docking structure of 10ZJ-EGFR. Dark color chains represent scaffolds. Hazy color chains represent domains 1, 2, 3 and 4 of EGFR, respectively. The residues in the circle represent the contact residues of the EGFR and scaffold. The structure of the scaffold of (a) was shown in the same direction as the scaffold structure in (b).
- (c) shows the energy contribution of the surface residues of 10 ZJ to form a complex with EGFR. Residues showing unstable binding energies selected for further improvement through directional evolution are indicated by bars. This indicates the amino acid residues that will later be mutated through randomization.
- Figure 5 shows the ELISA results showing the binding affinity when mutating the residue having an unstable binding energy of 10ZJ.
- the horizontal axis represents the clone number.
- the vertical axis represents the optical density obtained by ELISA analysis.
- the results of sequence randomization of the 10ZJ clone are shown in Table 2.
- FIG. 6 shows the amino acid sequence (left portion) and DNA sequence (right portion) of wild-type scaffolds prior to mutation through randomization of 10ZJ scaffolds.
- the underlined sequence is a sequence to be mutated to a residue showing an unstable binding energy.
- FIG. 7 shows the amino acid sequence (left portion) and DNA sequence (right portion) of clone 6 of the 10ZJ scaffold. Underlined sequences are sequences mutated to residues that exhibit instable binding energies.
- FIG. 8 shows the amino acid sequence (left portion) and DNA sequence (right portion) of clone 7 of the 10ZJ scaffold. Underlined sequences are sequences mutated to residues that exhibit instable binding energies.
- the present invention comprises the steps of (a) selecting a non-antibody protein having structural complementarity with the target site of the target protein in a library of non-antibody proteins; (b) calculating the binding energy of the selected non-antibody protein with the target protein; (c) selecting a non-antibody protein having stable binding energy among the selected non-antibody proteins: (d) selecting an amino acid residue having a high binding energy among amino acid residues in direct contact with the selected non-antibody protein and a target protein; step; And (e) replacing the amino acid residue selected in step (d) with an amino acid residue having a low binding energy.
- FIG. 1A The overall schematic of the method for producing the target specific non-antibody protein of the present invention is shown in FIG. 1A.
- the present inventors have prepared the present target specific non-antibody protein which performs the virtual screening step by docking simulation and binding energy calculation developed by the inventor and the directional evolution step using randomization of residues through phage display and biopanning.
- the method was named PELEX (Protein Engineering with Laboratory Evolution & Extensive Computation).
- non-antibody protein used in the present invention is a protein having a molecular weight of 10 to 40 kDa, the molecular weight of which is reduced to 1/10 or more compared to a conventional therapeutic antibody, and is easy to penetrate into target tissues, and mass production from bacteria and the like.
- a protein that is not a possible antibody it selectively recognizes and strongly binds to a specific target molecule that can be used for molecular target therapy, thereby inhibiting the activity of a desired target molecule to treat or prevent progression of various diseases such as cancer and autoimmune diseases. It means a protein that can be.
- Said “non-antibody protein” may be interchanged herein with "scaffold”, “scaffold protein”, "binding protein”.
- library of non-antibody proteins refers to the total collection of protein backbones consisting of the structures of all proteins whose human tertiary structure is found in nature, and such aggregates can be prepared to exist on a database. have.
- the preparation of a library of non-antibody proteins may use a database that includes all tertiary structures of human proteins such as Protein Data Bank (PDB) and Structural Classification of Protein (SCOP), but is not limited thereto.
- Proteins for the production of libraries of non-antibody proteins can be selected through various databases in which the three-dimensional structure of proteins is known. Such a database is classified into a plurality of groups according to types according to the three-dimensional structure of each human protein.
- the specific method for preparing the non-antibody protein library is as follows. First of all, only proteins having a molecular weight of 10 to 40 kDa may be selected in order to facilitate tissue penetration among human proteins. In this case, by selecting five or less representative proteins having a molecular weight of 10 to 40 kDa in each human protein structure type group, all types of human proteins may be included, and at the same time, the electronic library may be scaled down to improve the search speed. . Thereafter, as a step for removing non-antibody proteins among human proteins, the method may include removing membrane proteins and antibody proteins.
- Membrane proteins and antibody proteins can be used without limitation the database of known proteins, for example, can be performed using a keyword search or the like using a database such as Protein Data Bank of Transmembrane Proteins (PDBTM). . Thereafter, the method may include selecting only proteins of which 10 or less interactions are known to avoid indiscriminate binding. Information related to such interactions may also use a variety of databases that provide known protein-protein interaction information. For example, the number of protein interactions may be calculated using the Human Protein Reference Database (HPRD). Then one of monomer, homodimer, and homotrimer is used to exclude proteins that have many interactions at the same time, such as homotramers, homohexamers, etc.
- HPRD Human Protein Reference Database
- the method may include selecting a protein capable of forming an abnormality, and this may be performed by using a known database capable of calculating the binding between proteins, without limitation.
- a SWISS-PROT database may be used.
- the non-antibody protein library prepared through all of the above steps may include non-antibody proteins of which 1000 to 2000 structures are known.
- a non-antibody protein library consisting of 1261 non-antibody soluble proteins having a small molecular weight and low risk of random binding was prepared, and based on this, virtual screening such as docking simulation was performed.
- selecting a non-antibody protein having structural complementarity with a target d-site of the target protein in the library of non-antibody proteins; And (b) calculating the binding energy of the selected non-antibody protein and the target protein may be performed sequentially or simultaneously.
- target protein refers to a target protein to which a non-antibody protein binds, and may be variously selected according to the intended use through binding of the non-antibody protein, and may be a cancer-causing protein or an immune disease-causing protein.
- the foreign infectious protein may be selected without limitation, but may be an EGFR (Epidermal Growth Factor Receptor).
- target site is a site that directly or indirectly participates in pathological protein interaction and binding in the tertiary structure of the target protein, and the non-antibody protein strongly binds to the site to prevent malicious protein interaction.
- domain 2 of EGFR domain 2 of EGFR.
- the binding surface of the target protein to which the non-antibody protein of the present invention can bind can bind to various surfaces such as concave, so that the preparation of the non-antibody protein of the present invention is directed to the tertiary structure of the binding target protein. no limits.
- EGFR Extracellular Growth Factor Receptor
- EGFR Extracellular Growth Factor Receptor
- various cancer cells such as breast cancer, lung cancer, colon cancer, kidney cancer, gallbladder cancer, head and neck cancer, ovarian cancer, prostate cancer, cervical cancer and gastric cancer. It is overexpressed on the surface and is activated by the binding of growth factor EGF, which means the receptor of EGF that plays a central role in the proliferation, invasion, angiogenesis or metastasis of cancer cells.
- EGFR consists of four domains and is activated by forming a homodimer through exposed domain 2 through structural changes after binding to the ligand EGF. Therefore, the non-antibody protein that binds strongly to EGFR domain 2 targeted by the present invention specifically binds EGF, which is a ligand, to specifically bind to exposed domain 2, thereby preventing the formation of homodimers. May be inhibited (FIG. 3). Therefore, since it selectively inhibits only activated EGFR, it may function as a cancer treatment agent by selectively attacking only cancer cells, not normal cells.
- (A) selecting a non-antibody protein having structural complementarity with the target protein in the library of non-antibody proteins comprises using a supercomputer to target a plurality of non-antibody proteins or scaffolds in the library of the prepared non-antibody proteins. Checking whether there is a structural complementarity with, this can be done by performing a docking simulation to virtually combine. This is a process of virtually combining a plurality of scaffolds in a scaffold library with a target to create various binding structures. Docking simulation can use any known program without limitation.
- ZDOCK, PIPER, ClusPro, ICM- It may be a program such as DISCO, RosettaDock, PatchDock, MolFit, according to an embodiment of the present invention, using the PatchDock was selected for the non-antibody protein having structural complementarity.
- the PatchDock program ranks docking binding structures based on complementarity and the like.
- the binding structure in the 1st to 10th of the various binding structures for one non-antibody protein is selected and used in the subsequent analysis.
- the docking simulation step may select a non-antibody protein bound to a predetermined number or more among the target site amino acid residues of the target protein.
- the number of target residues to bind with the non-antibody protein may be 28, and the predetermined number is 10, and docking when 10 or more of the 28 residues participate in binding
- the scaffold binds to EGFR domain 2 in a stable structure
- non-antibody proteins forming such docking structures can be selected.
- the number of such residues can be variously set depending on the type of target protein or target site.
- Step (b) is a step of calculating the binding energy of the non-antibody protein and the target protein selected in the step (a), which is a non-antibody protein that binds to a desired site of the target protein well above a certain standard as a result of docking simulation This is a step for selecting. In this case, when the number of residues to be bound among the residues of the target site is a certain number or more can be made stable.
- the binding energy of the non-antibody protein and the target is calculated according to Equation 1 below.
- the binding energy may be calculated by various known programs, but is not limited thereto. For example, EGAD, RossettaDesign, or the like may be used. According to one embodiment of the invention the binding energy was calculated using the EGAD program.
- ⁇ G binding ⁇ G complex - ⁇ G free
- Binding energy is the energy required for the binding of the target protein and the non-antibody protein, and the energy of the combined state of the target protein and the non-antibody protein (G complex ) and the energy of each of the target protein and the non-antibody protein before binding ( G free ) Sort sequentially from the non-antibody protein with the lowest binding energy.
- Step (c) is a step of selecting a non-antibody protein having a stable binding energy from the selected non-antibody protein, the lower the binding energy, the more stable the binding of the target and the non-antibody protein, specific to the target It is more likely to combine strongly. At this time, it is preferable to set the desired number to align only the set number of non-antibody proteins.
- Step (d) is a step of selecting a residue having a high binding energy among amino acid residues in direct contact between the selected non-antibody protein and the target protein, and calculating the binding energy for each amino acid residue in direct contact with each residue to the binding energy. Calculate the degree of contribution. Residues with unstable binding energies can be chosen and used for later randomization. In this case, if the number of surface residues having an unstable binding energy is too large, it may be impossible in a later randomization process, and thus the exclusion may be performed through a relative comparison between upper scaffolds.
- the binding energy of each residue participating in the binding of 10ZJ selected as a stable scaffold with a high structural complementarity of binding energy among non-antibody proteins bound by EGFR domain 2 by docking simulation Five residues, 44Lys, 107 Glu, 110Glu, 114Asn, and 118Asp, the residues showing high binding energy were selected as unstable residues (FIG. 4C, Table 2).
- Step (e) is a step of replacing the unstable amino acid residue selected in step (d) with an amino acid residue having a low binding energy, and the binding energy is high because of the high binding energy among amino acid residues on the surface that bind between the target protein and the non-antibody protein. It is a directional evolutionary process that allows stable binding by replacing interfering amino acid residues with amino acids with low binding energy. Substitution of the amino acid residue can be used without limitation molecular known methods, but preferably may be carried out by performing phage display and bio panning process.
- the substitution energy of the residues 44Lys, 107 Glu, 110Glu, 114Asn and 118Asp, the residues showing the high binding energy by calculating the binding energy of each residue participating in the binding of the selected scaffold 10ZJ
- the clones were confirmed to have stronger binding than the wild-type 10ZJ scaffold through phage ELISA (FIG. 5).
- the inventors constructed a human scaffold library of 1,261 non-antibody soluble proteins having a molecular weight of 10 to 40 kDa and a low risk of random binding among proteins containing almost all known human proteins, followed by EGFR domain 2
- To screen scaffolds with complementary shapes we perform a large-scale docking simulation via the PatchDock program to select the top 10 binding models, and stabilize binding when 10 of the 28 residues of domain 2 of EGFR participate in the binding. Discriminant by structure, the protein scaffold having the shape most complementary to the binding region of EGFR domain 2 was found. The energy contribution involved in the binding of each residue of the selected scaffold was calculated via EGAD to select scaffold 10ZJ with the most stable complex formation energy and surface residues with five unstable binding energies (Table 1). And FIG.
- the present invention relates to a target specific non-antibody protein that specifically binds to EGFR domain 2.
- the target specific non-antibody protein that specifically binds to EGFR domain 2 is as described above, and preferably can be prepared by the method for producing the target specific non-antibody protein.
- the target specific non-antibody protein that specifically binds to the EGFR domain 2 may be the amino acid sequence of SEQ ID NO: 3, 4 or 5.
- the results of phage ELISA in 10ZJ selected as a target-specific non-antibody protein that specifically binds to EGFR domain 2 and analysis of the amino acid sequences of clones 6, 7 and 9 with increased binding capacity to EGFR It was confirmed that each had a sequence of SEQ ID NOs: 3, 4 and 5 (Table 2, Figures 5 and 7 to 9).
- the present invention relates to a nucleic acid encoding a target specific non-antibody protein that specifically binds to EGFR domain 2.
- a nucleic acid sequence encoding clones 6, 7, and 9 having increased binding ability with EGFR as a result of phage ELISA in 10ZJ selected as a target specific non-antibody protein that specifically binds to EGFR domain 2 As a result, it was confirmed that each had the sequence of SEQ ID NO: 7, 8 and 9 (Table 2, Fig. 5 and 7 to 9).
- the invention in another aspect, relates to a vector comprising a nucleic acid encoding a target specific non-antibody protein that specifically binds to EGFR domain 2.
- Vectors of the invention include, but are not limited to, plasmid vectors, cosmid vectors, bacteriophage vectors, viral vectors, and the like. Suitable expression vectors can include signal sequences or leader sequences for membrane targeting or secretion in addition to expression control elements such as promoters, operators, initiation codons, termination codons, polyadenylation signals and enhancers. The promoter of the vector may be constitutive or inducible.
- the expression vector also includes a selection marker for selecting a host cell containing the vector.
- the invention relates to a transformant transformed with a vector comprising a nucleic acid encoding a target specific non-antibody protein that specifically binds to EGFR domain 2.
- Transformation includes any method of introducing nucleic acids into an organism, cell, tissue or organ, and can be carried out by selecting appropriate standard techniques according to the host cell as known in the art. These methods include electroporation, protoplast fusion, calcium phosphate (CaPO4), precipitation, calcium chloride (CaCl2) precipitation, agitation with silicon carbide fibers, agro bacteria mediated transformation, PEG, dextran sulfate, Lipofectamine and the like, but is not limited thereto. Depending on the host cell, the expression level and the expression of the protein are different, so you can select and use the most suitable host cell for the purpose.
- Host cells include Escherichia coli, Bacillus subtilis, Streptomyces, Pseudomonas, Proteus mirabilis or Staphylococcus.
- Prokaryotic host cells such as, but are not limited to.
- fungi eg Aspergillus
- yeast eg Pichia pastoris, Saccharomyces cerevisiae
- Cells derived from higher eukaryotes, including lower eukaryotic cells such as Schizosaccharomyces and Neurospora crassa, insect cells, plant cells, mammals and the like, can be used as host cells.
- the present invention relates to a composition for treating or preventing cancer comprising a target specific non-antibody protein that specifically binds to EGFR domain 2.
- the cancer therapeutic or prophylactic composition of the present invention can be applied to all kinds of cancers generated by activation of EGFR, and can be applied to any animal in which the cancer can occur.
- Animals include, without limitation, humans and primates, as well as domestic animals such as cattle, pigs, sheep, horses, dogs, and cats.
- prevention refers to any action in which cancer induction is inhibited or delayed by administration of a composition comprising a non-antibody protein of the present invention
- treatment refers to administration of a composition containing a non-antibody protein of the present invention.
- cancer means all the actions that improve or beneficially change.
- the EGFR domain 2 specific non-antibody protein is coupled into the body in vivo in the form of a non-antibody protein-therapeutic conjugate, either directly or indirectly coupled (e.g., covalently) with an existing therapeutic agent or via a linker It can be used for cancer prevention or treatment.
- compositions for treating cancer comprising the EGFR domain 2 specific non-antibody protein of the present invention may further include a pharmaceutically acceptable carrier, and may be formulated with the carrier.
- pharmaceutically acceptable carrier refers to a carrier or diluent that does not irritate an organism and does not inhibit the biological activity and properties of the administered compound.
- Acceptable pharmaceutical carriers in compositions formulated as liquid solutions are sterile and physiologically compatible, including saline, sterile water, Ringer's solution, buffered saline, albumin injectable solutions, dextrose solution, maltodextrin solution, glycerol, ethanol and One or more of these components may be mixed and used, and other conventional additives such as antioxidants, buffers and bacteriostatic agents may be added as necessary. Diluents, dispersants, surfactants, binders and lubricants may also be added in addition to formulate into injectable formulations, pills, capsules, granules or tablets such as aqueous solutions, suspensions, emulsions and the like.
- An anticancer composition comprising a target specific non-antibody protein that specifically binds to EGFR domain 2 of the present invention and a pharmaceutically acceptable carrier is applicable to any formulation containing it as an active ingredient, oral or parenteral. It may be prepared in a dosage form.
- Pharmaceutical formulations of the invention may be oral, rectal, nasal, topical (including the cheek and sublingual), subcutaneous, vaginal or parenteral (intramuscular, subcutaneous). And forms suitable for administration by inhalation or insufflation.
- Oral dosage forms containing the composition of the present invention as an active ingredient include, for example, tablets, troches, lozenges, water-soluble or oily suspensions, preparation powders or granules, emulsions, hard or soft capsules, syrups or elixirs. can do.
- lactose For formulation into tablets and capsules, lactose, saccharose, sorbitol, mannitol, starch, amylopectin, binders such as cellulose or gelatin, excipients such as dicalcium phosphate, disintegrants such as corn starch or sweet potato starch, stearic acid masne It may include a lubricating oil such as calcium, calcium stearate, sodium stearyl fumarate or polyethylene glycol wax, and in the case of a capsule, it may further contain a liquid carrier such as fatty oil in addition to the above-mentioned materials.
- a lubricating oil such as calcium, calcium stearate, sodium stearyl fumarate or polyethylene glycol wax
- a liquid carrier such as fatty oil in addition to the above-mentioned materials.
- Formulations for parenteral administration comprising the composition of the present invention as an active ingredient, for injection, such as subcutaneous injection, intravenous injection or intramuscular injection, a suppository injection method or aerosol for spraying by inhalation through the respiratory system It can be formulated as.
- the compositions of the present invention may be mixed in water with stabilizers or buffers to prepare solutions or suspensions, which may be formulated for unit administration of ampoules or vials.
- solutions or suspensions which may be formulated for unit administration of ampoules or vials.
- a rectal composition such as suppositories or body enema including conventional suppository bases such as cocoa butter or other glycerides.
- a propellant or the like may be combined with the additives to disperse the dispersed dispersion or wet powder.
- a library of human protein scaffolds containing almost all of the known human proteins they are categorized into groups according to the three-dimensional structure of each human protein in the Structural Classification of Proteins (SCOP) database. Five representative structures were selected from the group. In order to facilitate tissue penetration, the molecular weight was limited to 5 or less representative proteins having a molecular weight of 10-40 kDa to include all types of human proteins while simultaneously reducing the size of the library. We then excluded the antibody by membrane protein structure and keyword search using annotations from the Protein Data Bank of Transmembrane Proteins (PDBTM) database. To avoid indiscriminate binding, only proteins with up to 10 known interactions were selected. The number of protein interactions was calculated by HPRD (Human Protein Reference Database).
- the result was a scaffold library of human protein structures consisting of 1,261 non-antibody soluble proteins with low molecular weight and low risk of random binding.
- the top 10 docking models were then selected from each scaffold-EGFR docking result, and the binding patterns of these models were analyzed to identify which residues of EGFR are involved in complex formation and to find the docking structure of EGFR domain 2.
- the scaffold is stabilized in the docking complex and EGFR domain 2 (the 166th amino acid of EGFR of SEQ ID NO: 1).
- the residue that undergoes a change larger than 1 ⁇ 2 in the solvent accessible surface area (SASA) was determined to be a residue involved in binding.
- SASA of each residue was calculated using Naccess (http://www.bioinf.manchester.ac.kr). This may determine whether a particular moiety participates in the binding.
- the complex formation energy of the scaffold-EGFR docking structure and the contribution of residues involved in each bond in the scaffold were calculated using EGAD (http://egad.berkeley.edu/EGAD_manual/index.html).
- the docking structure generated by PatchDock was used as a template, and the binding energy was calculated using complex_formation_energy in the JOBTYPE item of the command. All other options were used as default values.
- the pseudo_DELTA_G complex formation value was obtained as the complex formation energy, and the dG value of the surface residue represented by level_1 was collected to select an unstable residue.
- residues of level_2 which were indirectly involved in binding were excluded.
- two other criteria were considered. First, scaffolds with inappropriate structures were removed by manual inspection. Second, scaffolds where non-stable residues were placed close to each other in the primary sequence were preferred to facilitate the construction of random sequence libraries for directional evolution.
- ⁇ G binding ⁇ G complex - ⁇ G free
- Binding energy is the energy required to bind the target and the non-antibody binder protein.
- FIG. 4A B chain of 10ZJ (Crystal structure of Smad3-MH1) (FIG. 4A) was selected (Table 1).
- the complex formation energy of 10 ZJ against EGFR was calculated with a docking model (FIG. 4B).
- the scaffold is shown in dark color and the structure of the scaffold is shown in FIG. 4A in the same manner. Contact residues in the scaffold to EGFR are shown as spheres.
- amino acid residues that were unstable to form the complex through energy contribution experiments of each surface residue in the selected scaffold were selected for sequence randomization.
- 4C shows the results of energy contribution for each contact residue of 10ZJ, respectively.
- DNA (SEQ ID NO: 6, FIG. 6) of the EGFR binding scaffold (10ZJ) selected in Example 3 was synthesized in Genscript (Piscataway, NJ), and a NNK primer designed for randomization of a specific position of the binding region ( Genotech, Daejon, Korea). Randomized scaffolds were cut with Sfi I (Roche, Indianapolis, IN), ligated to phagemid vector pComb3X, and transformed into electrocompetent ER2738 (New England Biolabs, Beverly, Mass.) To prepare a random library.
- Dynabead M-270 Epoxy (Dynal, Invitrogen, Carlsbad, Calif.) According to the manufacturer's instructions. 5 x using PBS (137 mM sodium chloride, 10 mM phosphate, 2.7 mM potassium chloride, ph 7.4) to 1.5 ml EGFR (Sigma, St. Louis, MO) at 1 ml / mg 10 6 Dynabeads were coated each time of panning. Dynabead coated with EGFR was incubated with a 500 ⁇ l randomized phage library for 2 hours in a room temperature rotator.
- Each colony was randomly selected from the output titration plate at the end of the panning cycle and 1 ml of super broth (3% tryptone, 2% yeast extraction, 1% 3- [N-Morpholino] propanesulfonic acid [MOPS], pH 7.0) was inoculated. After overnight incubation at 37 ° C., the culture supernatant was used to perform a phage ELISA (enzyme-linked immunosorbant assay). Microtiter plate wells were coated with PBS containing 4 ⁇ g / ml EGFR overnight at 4 ° C. and blocked with PBS containing 3% BSA at 37 ° C. for 1 hour.
- the plates were incubated with the culture supernatant containing phage for 2 hours at 37 ° C. and washed three times with PBS (PBST) containing 0.05% Tween-20. Then, anti-M13 antibody (Sigma) bound to diluted HRP (horseradish peroxidase) in blocking buffer (1: 2000) was added and incubated at 37 ° C for 1 hour. 50 ⁇ l TMB substrate solution (Pierce, Rockford, IL) was added to each well and OD was measured at 650 nm.
- PBST PBS
- HRP horseradish peroxidase
- Clone 7 had an amino acid sequence of SEQ ID NO: 4 and a DNA sequence of SEQ ID NO: 9 (FIG. 8).
- Clone 9 had an amino acid sequence of SEQ ID NO: 5 and a DNA sequence of SEQ ID NO: 8 (FIG. 9).
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Theoretical Computer Science (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Evolutionary Biology (AREA)
- Medical Informatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Library & Information Science (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Toxicology (AREA)
- Computing Systems (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims (17)
- (a) 비항체 단백질의 라이브러리에서 표적 단백질의 표적 부위와 구조적 상보성을 가지는 비항체 단백질을 선별하는 단계;(b) 상기 선별된 비항체 단백질과 표적 단백질의 결합에너지를 계산하는 단계;(c) 상기 선별된 비항체 단백질 중에서 안정적인 결합에너지를 갖는 비항체 단백질을 선별하는 단계:(d) 선정된 비항체 단백질과 표적 단백질이 직접 접촉하는 아미노산 잔기 중 결합에너지가 높은 아미노산 잔기를 선택하는 단계; 및(e) 상기 (d) 단계에서 선택된 아미노산 잔기를 결합에너지가 낮은 아미노산 잔기로 치환하는 단계를 포함하는, 표적 특이적 비항체 단백질의 제조 방법.
- 제1항에 있어서, 상기 (a) 단계 및 (b) 단계는 순차적으로, 또는 동시에 수행될 수 있는 것인 표적 특이적 비항체 단백질의 제조 방법.
- 제1항에 있어서, 상기 (a) 단계의 비항체 단백질 라이브러리는 인간 단백질 중 10 내지 40kDa의 분자량의 가지고, 단량체 (monomer), 동종이량체 (homodimer), 및 동종삼량체 (homotrimer) 중 어느 하나 이상을 형성할 수 있는 비항체 단백질을 포함하는 것인 표적 특이적 비항체 단백질의 제조 방법.
- 제1항에 있어서, 상기 (a) 단계의 라이브러리는(i) 인간 단백질 중 10 내지 40kDa의 분자량을 갖는 단백질을 선택하는 단계;(ii) 상기 (i) 단계에서 선택된 단백질에서 막 단백질 및 항체 단백질을 제거하는 단계;(iii) 상기 (ii) 단계에서 제거하고 남은 단백질에서 10개 이하의 상호작용이 알려진 단백질을 선택하는 단계; 및(iv) 상기 (iii) 단계에서 선택된 단백질에 단량체 (monomer), 동종이량체 (homodimer), 및 동종삼량체 (homotrimer) 중 어느 하나 이상을 형성할 수 있는 단백질을 선택하는 단계를 포함하는 방법으로 제조하는 것인, 표적 특이적 비항체 단백질의 제조 방법.
- 제1항에 있어서, 상기 (a) 단계는 도킹 시뮬레이션을 수행하여 선별하는 것인 표적 특이적 비항체 단백질의 제조 방법.
- 제5항에 있어서, 상기 (a) 단계의 도킹 시뮬레이션은 상기 표적 단백질의 아미노산 잔기들 중 기 설정된 개수 이상 결합되는 비항체 단백질을 선택하는 단계인 표적 특이적 비항체 단백질의 제조 방법.
- 제1항에 있어서, 상기 (e) 단계는 파지 디스플레이 및 바이오 패닝 (biopanning)을 수행하여 이루어지는 것인 표적 특이적 비항체 단백질의 제조 방법.
- 제1항에 있어서, 상기 (a) 단계의 표적 단백질은 EGFR (Epidermal Growth Factor Receptor) 도메인 2인 것인 표적 특이적 비항체 단백질의 제조 방법.
- 제8항에 있어서, 상기 (a) 단계는 상기 표적 단백질의 잔기는 28개이고, 상기 기 설정된 개수는 10개인 것인 표적 특이적 비항체 단백질의 제조 방법.
- EGFR 도메인 2에 특이적으로 결합하는 표적 특이적 비항체 단백질.
- 제10항에 있어서, 상기 표적 특이적 비항체 단백질은 제1항 내지 제9항 중 어느 한 항의 방법으로 제조하는 것인 표적 특이적 비항체 단백질.
- 제11항에 있어서, 상기 표적 특이적 비항체 단백질은 서열번호 3, 4 또는 5의 아미노산 서열을 갖는 것인 표적 특이적 비항체 단백질.
- 제10항의 비항체 단백질을 코딩하는 핵산.
- 제13항에 있어서, 상기 핵산은 서열번호 7, 8 또는 9의 핵산 서열을 갖는 것인 핵산.
- 제13항의 핵산을 포함하는 벡터.
- 제15항의 벡터로 형질전환된 형질전환체.
- 제10항의 비항체 단백질을 포함하는 암치료용 조성물.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201080020628.8A CN102421789B (zh) | 2009-04-15 | 2010-04-14 | 靶特异性非抗体蛋白质及其制备方法 |
JP2012505820A JP5584752B2 (ja) | 2009-04-15 | 2010-04-14 | 標的特異的非抗体タンパク質及びこの製造方法 |
US13/264,365 US9296802B2 (en) | 2009-04-15 | 2010-04-14 | Target-specific non-antibody protein and method for preparing the same |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16963609P | 2009-04-15 | 2009-04-15 | |
US61/169,636 | 2009-04-15 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2010120121A2 true WO2010120121A2 (ko) | 2010-10-21 |
WO2010120121A3 WO2010120121A3 (ko) | 2011-03-10 |
Family
ID=42983002
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2010/002318 WO2010120121A2 (ko) | 2009-04-15 | 2010-04-14 | 표적 특이적 비항체 단백질 및 이의 제조 방법 |
Country Status (5)
Country | Link |
---|---|
US (1) | US9296802B2 (ko) |
JP (1) | JP5584752B2 (ko) |
KR (1) | KR101047192B1 (ko) |
CN (1) | CN102421789B (ko) |
WO (1) | WO2010120121A2 (ko) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113727994A (zh) * | 2019-05-02 | 2021-11-30 | 德克萨斯大学董事会 | 提高合成蛋白质稳定性的系统和方法 |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101400717B1 (ko) | 2012-12-28 | 2014-05-29 | (주)신테카바이오 | 전체원자기반 고분자 복합체의 시뮬레이션 시스템 및 방법 |
CN108884127A (zh) * | 2016-01-21 | 2018-11-23 | 斯克利普斯研究院 | 合成的阿片类疫苗 |
US11074992B2 (en) | 2016-04-12 | 2021-07-27 | Andrew Ka-Ching WONG | Method for determining interaction sites between biosequences |
US11124575B2 (en) | 2017-02-22 | 2021-09-21 | University Of Saskatchewan | EGFR-binding agents and uses thereof |
US11450407B1 (en) | 2021-07-22 | 2022-09-20 | Pythia Labs, Inc. | Systems and methods for artificial intelligence-guided biomolecule design and assessment |
US11742057B2 (en) * | 2021-07-22 | 2023-08-29 | Pythia Labs, Inc. | Systems and methods for artificial intelligence-based prediction of amino acid sequences at a binding interface |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20080099278A (ko) * | 2006-01-23 | 2008-11-12 | 조셉 피. 에리코 | 표적 약물 개발의 방법 및 조성물 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU3198899A (en) * | 1998-03-20 | 1999-10-11 | Rockefeller University, The | Assays for screening compounds which interact with cation channel proteins, mutant prokaryotic cation channel proteins, and uses thereof |
CN1826129A (zh) * | 2002-07-09 | 2006-08-30 | 尖端医疗有限公司 | 与异亮氨酸硼脯氨酸化合物相关的方法和组合物 |
WO2004052302A2 (en) * | 2002-12-10 | 2004-06-24 | The Regents Of The University Of California | A method for creating specific, high affinity nuclear receptor pharmaceuticals |
CN1237185C (zh) * | 2003-06-04 | 2006-01-18 | 中国科学院上海药物研究所 | Sars冠状病毒3cl蛋白酶三维结构模型与抗sars药物 |
US20070009972A1 (en) * | 2005-02-16 | 2007-01-11 | Ginger Chao | Epidermal growth factor receptor polypeptides and antibodies |
CN1730665A (zh) * | 2005-08-03 | 2006-02-08 | 华东理工大学 | 一种pi3k酶抑制剂的快速筛选方法 |
CN101205555A (zh) * | 2006-12-18 | 2008-06-25 | 中国疾病预防控制中心寄生虫病预防控制所 | 抗日本血吸虫药物作用靶标、药物筛选方法及药物先导化合物 |
KR101127476B1 (ko) * | 2008-08-11 | 2012-03-23 | 아주대학교산학협력단 | 크링글 도메인의 구조에 기반한 단백질 골격 라이브러리 및 그 용도 |
-
2010
- 2010-04-14 WO PCT/KR2010/002318 patent/WO2010120121A2/ko active Application Filing
- 2010-04-14 KR KR1020100034505A patent/KR101047192B1/ko not_active IP Right Cessation
- 2010-04-14 US US13/264,365 patent/US9296802B2/en not_active Expired - Fee Related
- 2010-04-14 CN CN201080020628.8A patent/CN102421789B/zh not_active Expired - Fee Related
- 2010-04-14 JP JP2012505820A patent/JP5584752B2/ja not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20080099278A (ko) * | 2006-01-23 | 2008-11-12 | 조셉 피. 에리코 | 표적 약물 개발의 방법 및 조성물 |
Non-Patent Citations (3)
Title |
---|
HEY, T. ET AL. TRENDS BIOTECHNOL. vol. 23, no. 10, October 2005, pages 514 - 522 * |
OGISO, H. ET AL. CELL vol. 110, no. 6, 20 September 2002, pages 775 - 787 * |
SKERRA, A. CURR. OPIN. BIOTECHNOL. vol. 18, no. 4, August 2007, pages 295 - 304 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113727994A (zh) * | 2019-05-02 | 2021-11-30 | 德克萨斯大学董事会 | 提高合成蛋白质稳定性的系统和方法 |
Also Published As
Publication number | Publication date |
---|---|
JP2012523248A (ja) | 2012-10-04 |
KR20100114478A (ko) | 2010-10-25 |
US9296802B2 (en) | 2016-03-29 |
CN102421789A (zh) | 2012-04-18 |
CN102421789B (zh) | 2015-02-25 |
JP5584752B2 (ja) | 2014-09-03 |
KR101047192B1 (ko) | 2011-07-06 |
US20120071419A1 (en) | 2012-03-22 |
WO2010120121A3 (ko) | 2011-03-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2010120121A2 (ko) | 표적 특이적 비항체 단백질 및 이의 제조 방법 | |
US7667004B2 (en) | Humanized antibodies against vascular endothelial growth factor | |
CN103328507B (zh) | Alphabody文库及其产生方法 | |
KR100245767B1 (ko) | 무작위바이오-올리고머 라이브러리, 라이브러리의 합성방법 그리고 이의 이용방법 | |
KR100829972B1 (ko) | 항-hgf/sf 인간화 항체 및 이의 제조방법 | |
Pandey et al. | Identification of a potent combination of key Plasmodium falciparum merozoite antigens that elicit strain-transcending parasite-neutralizing antibodies | |
Lu et al. | Profiling the humoral immune responses to Plasmodium vivax infection and identification of candidate immunogenic rhoptry-associated membrane antigen (RAMA) | |
JP2017018124A (ja) | 安定したフィブロネクチンドメイン組成物、方法及び用途 | |
Li et al. | Phage-displayed peptides bind to the malarial protein apical membrane antigen-1 and inhibit the merozoite invasion of host erythrocytes | |
JP2010187667A (ja) | 単量体ドメインの組み合わせライブラリー | |
Tonelli et al. | Selection of binding targets in parasites using phage-display and aptamer libraries in vivo and in vitro | |
Miceli et al. | Two-stage selection of sequences from a random phage display library delineates both core residues and permitted structural range within an epitope | |
Ma et al. | Eimeria tenella: specific EtAMA1-binding peptides inhibit sporozoite entry into host cells | |
Jonsson et al. | Generation of tumour‐necrosis‐factor‐α‐specific affibody 1 molecules capable of blocking receptor binding in vitro | |
Lundquist et al. | Human recombinant antibodies against Plasmodium falciparum merozoite surface protein 3 cloned from peripheral blood leukocytes of individuals with immunity to malaria demonstrate antiparasitic properties | |
Adda et al. | Isolation of peptides that mimic epitopes on a malarial antigen from random peptide libraries displayed on phage | |
JPWO2007119518A1 (ja) | 抗メチル化dna抗体及びその作製方法 | |
WO2023070036A1 (en) | Neutralizing trivalent protein-dna molecules (tri-pdbody) for sars-cov-2 infection treatment | |
JP2020525033A (ja) | アセチルコリン受容体結合ペプチド | |
Alba et al. | Modifying RESA protein peptide 6671 to fit into HLA-DRβ1* pockets induces protection against malaria | |
DK1262546T3 (da) | Hidtil ukendte scavenger-receptorer | |
Morell et al. | Structural characterization of the main immunogenic region of the Torpedo acetylcholine receptor | |
WO2023025147A1 (zh) | 抗原表位修饰 | |
CN116875606A (zh) | 肠出血性大肠杆菌志贺毒素ⅱ型b亚基适配体的结构优化及应用 | |
WO2023070030A1 (en) | Nanoscale dna-peptide hybrid molecules for multivalent protein binding |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201080020628.8 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10764660 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012505820 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13264365 Country of ref document: US |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 10764660 Country of ref document: EP Kind code of ref document: A2 |